Evidence map›Paper›PMID 40491921›Full record

ArticleFrontiers in immunology2025

GSDMD is a novel predictive biomarker for immunotherapy response: in the pan-cancer and single cell landscapes.

Li Juan Huang, Feng Chen, Lin Chen, Shi Tong Zhan, Ming Min Liu, Jiang Dong Xiang, Qin Yi Zhang, Ye Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Li Juan Huang *Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Feng Chen *Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lin ChenObstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shi Tong ZhanObstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ming Min LiuObstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiang Dong Xiang *Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qin Yi Zhang *Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ye Yang *Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gasdermin D (GSDMD), a key executor of pyroptosis, has been implicated in modulating the tumor immune microenvironment. However, its role as a predictive biomarker for immunotherapy response remains unclear. Methods: We conducted a pan-cancer analysis of GSDMD expression across TCGA datasets and investigated its association with tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status. Immunological relevance was further assessed by correlating GSDMD expression with immune cell infiltration and immune checkpoint gene signatures. We performed single-cell RNA sequencing analysis to investigate the immune cell populations and immunological pathways associated with GSDMD expression. Finally, organoid-based functional assays confirmed that Poly ADP-ribose polymerase inhibitors (PARPi) exert antitumor effects at least in part by enhancing GSDMD-mediated pyroptosis. Results: GSDMD was found to be aberrantly expressed in multiple tumor types and positively correlated with TMB, MSI, and immune checkpoint expression. High GSDMD expression was associated with increased infiltration of pro-inflammatory immune cells. In organoid models, GSDMD expression influenced sensitivity to PARPi, suggesting a potential role in shaping the immune-responsive phenotype. Conclusion: Our findings highlight GSDMD as a potential biomarker for predicting immunotherapy response and as a modulator of tumor-immune interactions. These results provide a foundation for future studies exploring GSDMD-targeted strategies to enhance immunotherapeutic efficacy.

Indexed as

Biomarkers, TumorImmunotherapyIntracellular Signaling Peptides and ProteinsNeoplasmsPhosphate-Binding ProteinsPore Forming Cytotoxic ProteinsGasderminsGene Expression Regulation, NeoplasticHumansMicrosatellite InstabilityPyroptosisSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorGasderminsGSDMD protein, humanIntracellular Signaling Peptides and ProteinsPhosphate-Binding ProteinsPore Forming Cytotoxic ProteinsGSDMDimmunotherapypan-cancerprognosispyroptosis

Identifiers

PMID40491921
PMCPMC12146313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.